|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:FOLFIRI
docetaxel
paclitaxel
|
|
gptkbp:approvalYear
|
2014
2014-04-21
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:FDA
colorectal cancer
hepatocellular carcinoma
gastric cancer
|
|
gptkbp:ATCCode
|
L01XC21
|
|
gptkbp:CASNumber
|
945721-28-8
|
|
gptkbp:contraindication
|
hypersensitivity to ramucirumab
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:ramucirumab
|
|
gptkbp:halfLife
|
~14 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cyramza
|
|
gptkbp:indication
|
metastatic non-small cell lung cancer
metastatic colorectal cancer
advanced or metastatic gastric cancer
hepatocellular carcinoma after sorafenib
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
VEGFR-2 antagonist
|
|
gptkbp:MedlinePlusID
|
a614048
|
|
gptkbp:monoclonalAntibodyType
|
human IgG1
|
|
gptkbp:patent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.cyramza.com/
|
|
gptkbp:PubChem_CID
|
CHEMBL2108507
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
bleeding
headache
hypertension
proteinuria
|
|
gptkbp:target
|
gptkb:VEGFR-2
|
|
gptkbp:UNII
|
Q1J8A4N5FD
|
|
gptkbp:bfsParent
|
gptkb:Lilly_Oncology
gptkb:Ramucirumab
gptkb:ramucirumab
|
|
gptkbp:bfsLayer
|
7
|